NeuroVive buys stake in Isomerase Therapeutics Lund,

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Jan 14, 2016 at 4:15 AM

NeuroVive buys stake in Isomerase Therapeutics

Lund, Sweden, 14 January 2016 – NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces the partial acquisition of British company Isomerase Therapeutics (“Isomerase”) with the overall goal to strengthen the partnership and accelerate NeuroVive’s research and development (R&D) program. The acquisition aims to further enhance the collaboration and to ensure that NeuroVive’s projects remain a key priority for Isomerase. Furthermore, the partnership will support the discovery of new compounds, based on the additional expertise Isomerase brings to the partnership. This is a key step forward for NeuroVive, who are committed to advancing the R&D portfolio as quickly as possible. Most recently, the joint teams at NeuroVive and Isomerase have been able to advance the drug candidate process for the Complex I program (NVP015) and the project is progressing well. “We highly value our strong partnership with the team at Isomerase and want to ensure we remain aligned on project priorities moving forward. Isomerase brings additional expertise to the table which supports our R&D efforts and allows us to both accelerate our current R&D program as well as identify new compounds to fuel our future portfolio” said Jan Nilsson, interim CEO of NeuroVive Pharmaceutical. “Through our collaboration with Isomerase, our discovery platform for complex I deficiency has already seen advancements through the generation of new molecules and we expect to further progress this project as the aim is to select a drug candidate for preclinical development in 2016” continued Jan Nilsson. Isomerase is a world leader in the discovery and development of molecules that target peptidyl-prolyl isomerases such as cyclophilins. The team is actively involved in the pharmacology, chemistry and manufacturing for many of NeuroVive’s projects. "We have built up a very strong relationship with the team at NeuroVive over the last couple of years and this partial acquisition is a natural extension of this. It will enable us to take part in the future success of NeuroVive’s exciting early stage projects and in return give NeuroVive confidence that we are fully engaged with our excellent collaboration. We also hope that it will enable NeuroVive to access future returns on our new ground-breaking drug discovery technologies and our own early stage in-house drug discovery projects." said Matt Gregory, CEO of Isomerase Therapeutics. The acquisition will be executed in two steps. The first step in the acquisition was executed on January 13, 2016 when NeuroVive acquired approximately 5% shares in Isomerase with payment in own shares. The next step in the acquisition will be completed later this year where NeuroVive will acquire approximately 5% further of the shares in Isomerase as a cash payment of 550 000 GBP. In order to make payment for the shares in Isomerase acquired January 13, 2016, the NeuroVive board of directors approved the same day, with prior authorization from the AGM on March 30 2015, the issue of 738,533 new shares. The purchase price for the first step amounting to approximately 6.8 million was based on the average closing price of NeuroVive shares on Nasdaq Stockholm from 23 December 2015 to January 12, 2016 inclusive. The Non-Cash Consideration increases the number of shares of NeuroVive with an additional 738,533 shares from 30,735,152 shares to 31,473,685 shares in total and increases the share capital by SEK 36,926.65 from SEK 1,536,757.60 to SEK 1.573.684.25 in total. The Non-Cash Consideration entails a dilution of approximately 2.4%. About NeuroVive NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, is committed to the discovery and development of highly targeted candidates that preserve mitochondrial integrity and function in areas of therapeutic need. NeuroVive’s business approach is driven by value-adding partnerships with leading research institutions and commercial partners across the globe. NeuroVive’s portfolio consists of two clinical projects in acute kidney injury (AKI) and traumatic brain injury (TBI) with candidates in clinical and preclinical development and two drug discovery platforms. NeuroSTAT® has orphan drug status in Europe and in the US for treatment of moderate to severe traumatic brain injury and is currently being evaluated in a Phase II study (CHIC). CicloMulsion® is being evaluated in an ongoing Phase II study (CiPRICS) in acute kidney injury during major surgery. NeuroVive’s shares are listed on Nasdaq Stockholm, Sweden. For investor relations and media questions, please contact: Johannes Nebel, Laika Consulting, Tel: +46 (0)735 81 71 68 or ir@neurovive.com It is also possible to arrange an interview with NeuroVive’s interim CEO Jan Nilsson at the above contacts. NeuroVive Pharmaceutical AB (publ) Medicon Village, SE-223 81 Lund, Sweden Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48 info@neurovive.com (info@neurovive.com), www.neurovive.com NeuroVive Pharmaceutical AB (publ) is required to publish the information in this news release under The Swedish Securities Market Act. The information was submitted for publication on the 14 January 2016, at 08.30 CET.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Standards Touch 2027 Student Paper Competition

Diving into Trust: ANSI's 2027 Paper Challenge Out from the buzz of New York, the American National Standards Institute (ANSI) has stirred up some real brain-teasing talk for students across the country. Kicking off the 2027 Student Paper Competition, they're handing students a chance to ponder a question we take for granted every day. Do we ever truly consider what makes...

Glance's Guide Bridges AI and Human Service Gaps

Untangling the AI to Human Transition Ever found yourself stuck in a never-ending loop with AI, screaming for a human voice? You're not alone. According to Glance's 2026 Customer Experience Trends Report, a staggering 76% of consumers are pulling their hair out while repeating themselves when switching service channels. The rub? Only 7% claim they rarely experience this...

Okta Joins S&P 500 Amidst Major Index Shuffles

Okta Leaps to S&P 500: A Power Play You blink for a second, and boom, Okta's sitting at the big kids' table—the S&P 500. You know how rare that move is? It’s like snagging an invite to the party everyone wants to attend. Swapping out Kenvue Inc. (NYSE: KVUE), which Kimberly-Clark (NASD: KMB) is scooping up, Okta's maneuver signifies a hefty endorsement of its growth...

Aemetis Faces Class Action Over Wage Violation Claims

California's Alert: Labor Code Violations Under Scrutiny Allegations like these can shake things up pretty quick, especially when you're dealing with harsh financial climates. Aemetis Advanced Fuel Keyes, Inc. is in hot water yet again—this time, they're being called out for allegedly messing up the wage game for their workers. That's right, a class action lawsuit filed...

Federal Realty Boosts Outlook with Q3 Gains

Numbers That Matter: Solid Q3 Performance Federal Realty Investment Trust's (NYSE: FRT) latest numbers paint a rosy picture—fading the gloom and doom for the moment. The steady climb from $0.69 to $0.74 in diluted EPS from last year is one thing, but it’s the 5.6% boost in Nareit-defined and Core funds from operations per diluted share that's catching eyes, now...

Flash Tech Sparks New Era in Gas Sensing

By Caleb Price Updated Oct 30, 2026 Category News Views 38

Revolutionary 10-Millisecond Flash Technique Out of South Korea comes a scientific shake-up that's got eyes on a tiny flash of light poised to change gas sensing technology as we know it. Yep, at Hanyang University ERICA, the boffins have figured out how a quick-fire 10-millisecond zap can turn up the sensitivity dial on gas sensors, especially for the pesky nitrogen...

CACI Hits $50K Milestone in Service Dog Program

Ice Blocking for a Noble Cause Last I checked, mixing the adrenaline of ice hockey with the grit of veteran support isn't your typical skate on thin ice. But CACI International Inc (NYSE:CACI), with their Good Dogs for Great Americans program, is doing just that. They're taking every blocked shot by the Washington Capitals and turning it into a stepping stone for veterans...

Jewelry Repair and Resizing Demystified by Expert

The Magic of Fixing Sparkles When it comes to keeping those sparkly trinkets as charming as ever, nothing beats a well-timed fix-up. Jewelry repair isn’t just about patching up old necklaces or battered rings; it’s an art of bringing worn-out pieces back to life. I’m talking about the sort of work that Mike Littlejohn at Carbaugh Jewelers breaks down in a recent...

Hisense's RGB MiniLED TVs: Redefining Halloween Viewing

A New Dimension to Halloween's Visuals You ever notice how some TVs just can’t do justice to a Halloween flick? It’s all about the details—those rich, spooky colors and the perfectly balanced light and shadow. The nuance in the shadowy folds of a cape or the eerie glow of a lantern is crucial. Hisense's RGB MiniLED technology is showing up just in time to rescue...

Hot Chili Sizzles with La Verde Copper Drill Gains

Big Copper Moves at La Verde: What's New? Look, when it comes to copper, Hot Chili Limited is throwing down some serious markers. You see, their La Verde project is turning into a hotbed of activity thanks to their latest drilling revelations. They've managed to confirm a second porphyry center, which is like finding another gold mine, except with copper. This essentially...